TSH Receptor Antibodies (TRAb) in Suspected Graves Disease
When to Measure TRAb
Measure TRAb when the clinical presentation does not clearly indicate Graves disease, when thyroid nodules are present, or when the presentation suggests toxic adenoma or multinodular goiter. 1
Primary Diagnostic Indications
- Differential diagnosis of hyperthyroidism when clinical features are ambiguous—TRAb testing has excellent diagnostic performance with sensitivity and specificity both exceeding 95% using third-generation assays 2
- Presence of thyroid nodules on examination or imaging, regardless of size 1
- Clinical features suggesting alternative diagnoses such as toxic adenoma or toxic multinodular goiter 1
- Atypical presentations including unilateral exophthalmos, euthyroid Graves ophthalmopathy, subclinical hyperthyroidism, thyrotoxicosis with hyperemesis gravidarum, amiodarone-induced thyrotoxicosis, or painless thyroiditis 3
When TRAb Testing is NOT Necessary
- Classic Graves disease presentation with diffuse goiter and exophthalmia—scintigraphy may be non-contributive to diagnosis in these obvious cases 1
- However, even in classic cases, TRAb measurement can help guide treatment decisions and predict outcomes 4
Interpretation of TRAb Results
Diagnostic Thresholds
- Cutoff value of 1.45 IU/L provides 100% specificity and 98.3% sensitivity for diagnosing Graves disease at initial presentation 5
- Positive TRAb (>1.45 IU/L) confirms Graves disease with high certainty 6
- Negative TRAb makes Graves disease unlikely but does not completely exclude it—approximately 18% of Graves disease patients may be TRAb-negative at diagnosis 7
Clinical Characteristics by TRAb Level
- TRAb-negative Graves disease patients (18% of cases) have markedly less severe clinical and laboratory hyperthyroidism, smaller goiters, and lower smoking rates compared to TRAb-positive patients 7
- Higher TRAb levels correlate with male gender, smoking status, larger goiter size, presence of Graves ophthalmopathy, higher fT3 levels, and positive anti-TPO antibodies 7
- Smoking male patients have the highest TRAb levels and most severe clinical hyperthyroidism 7
Prognostic Use: Predicting Remission and Relapse
Measure TRAb before stopping antithyroid drug therapy, as normal levels indicate greater chance for remission. 4
Timing of Prognostic Measurements
- At diagnosis: TRAb >12 IU/L predicts 60% relapse risk at 2 years and 84% at 4 years 8
- At 12 months of therapy: TRAb >7.5 IU/L predicts >90% relapse risk 8
- At cessation of antithyroid drugs (12-18 months): TRAb >3.85 IU/L predicts relapse with 85.3% sensitivity and 96.5% specificity 5
Specific Prognostic Thresholds
- TRAb <0.9 IU/L at end of treatment: All patients remained euthyroid throughout follow-up 5
- TRAb 0.9-4.4 IU/L: Intermediate zone that does not reliably discriminate between remission and relapse 5
- TRAb >3.85 IU/L at withdrawal: 96.7% positive predictive value for relapse, typically occurring within 8 weeks 5
- TRAb <3.85 IU/L with subsequent relapse: Hyperthyroidism develops later (median 56 weeks) and is always accompanied by rising TRAb levels 5
Pediatric Considerations
- TRAb levels persist longer in children than adults—only 18% of pediatric patients normalize TRAb after 24 months of antithyroid drug therapy 4
- The utility of TRAb monitoring for predicting remission in children has not been validated, unlike in adults 4
Pregnancy-Specific Indications
Measure TRAb in all pregnant women with current or previously treated Graves disease to assess risk of fetal and neonatal thyrotoxicosis. 4
Pregnancy Testing Protocol
- When etiology of hyperthyroidism is uncertain in pregnancy 4
- Women treated with radioactive iodine or thyroidectomy prior to pregnancy: Measure TRAb using sensitive assay either initially at 22-26 weeks gestation, or initially during first trimester and again at 22-26 weeks if elevated 4
- Women diagnosed with Graves disease during pregnancy: Measure at diagnosis and again at 22-26 weeks if elevated 4
- TRAb ≥5 IU/L in pregnancy: Associated with increased risk of fetal and neonatal thyrotoxicosis requiring close monitoring 8
- Negative TRAb in pregnancy: Highly unlikely to result in fetal hyperthyroidism 2
Graves Ophthalmopathy
- Patients with Graves ophthalmopathy frequently have high TRAb levels 2
- Elevated TRAb is an indication for steroid prophylaxis to prevent progression of ophthalmopathy with radioactive iodine therapy 8
- However, insufficient data exist to use TRAb for predicting clinical course of ophthalmopathy or response to treatment 2
Common Pitfalls and Caveats
Assay Limitations
- Second- and third-generation assays are required for optimal clinical utility—older first-generation assays have inadequate sensitivity and specificity 2, 8
- Blocking TSH receptor antibodies cannot be reliably detected in patients with Graves disease because stimulating antibodies may overwhelm their measurement in available bioassays 9
- TSI (thyroid stimulating immunoglobulin) and TRAb are strongly correlated (r=0.873), and both can be used for diagnosis and prognosis 10
Dynamic Changes During Treatment
- TRAb levels decline with antithyroid drug therapy and after thyroidectomy 8
- TRAb levels increase for one year following radioactive iodine therapy, then gradually fall thereafter 8
- Persistently elevated TRAb after 18 months of methimazole suggests maintained stimulating activity, though antibody potency and/or thyroid response may change during treatment 5
Treatment Decision Algorithm
- Elevated TRAb at diagnosis or during follow-up favors definitive treatment (radioactive iodine or thyroidectomy) over continued antithyroid drugs 8
- Choice between radioactive iodine versus thyroidectomy depends on presence/absence of moderate-to-severe Graves ophthalmopathy and ability to comply with radiation protection requirements 8
- Women of childbearing age with high relapse risk (elevated TRAb) should consider early ablative treatment given increased risk of congenital anomalies with antithyroid drug use in early pregnancy 8